Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience.

Andrew SchaeferYing HuangAdam KittaiJoseph E MaakaronCaner SayginJonathan BrammerSam PenzaAyman SaadSamantha M JaglowskiBasem M William

Published in: Cancer management and research (2021)

Our data suggest a correlation between cytopenias and survival outcomes after CD19 CAR-T therapy. If validated, cytopenia may be proven useful as a biomarker of response and survival after CAR-T therapy.

Keyphrases

electronic health record
nk cells
low grade
deep learning